Phil Raess, M.D., Ph.D.

  • Assistant Professor of Pathology, School of Medicine
  • Program Director, Hematopathology Fellowship
  • Medical Director, Immunohistochemistry Lab


  • B.S., 2001, Indiana University
  • M.D., Ph.D., 2009, University of Wisconsin
  • Residency:

    • Anatomic and Clinical Pathology, Hospital of the University of Pennsylvania, 2009-2013
  • Fellowship:

    • Surgical Pathology, Oregon Health & Science University, Portland, Oregon, 2013-2014
    • Hematopathology, Oregon Health & Science University, Portland, Oregon, 2014-2015
  • Certifications:

    • Anatomic and Clinical Pathology (American Board of Pathology), 2013
    • Hematopathology (American Board of Pathology), 2015

Areas of interest

  • Clinical interests: Molecular pathology, hematopathology, and digital pathology
  • Research interests: The pathogenesis of various types of lymphoma, the effect of molecular events on tumor phenotype and prognosis, and development of novel diagnostic approaches for challenging hematopathology cases.


Selected publications

  • Select publications (full PubMed bibliography link in Additional Information) 
  • MYC immunohistochemical and cytogenetic analysis are required for identification of clinically relevant aggressive B cell lymphoma subtypes. Raess PW, Moore SR, Cascio MJ, Dunlap J, Fan G, Gatter K, Olson SB, Braziel RM. Leukemia & Lymphoma. 2018 Jun. PMID: 28868942.
  • Concurrent STAT3, DNMT3A, and TET2 mutations in T-LGL leukemia with molecularly distinct clonal hematopoiesis of indeterminate potential. Raess PW, Cascio MJ, Fan G, Press R, Druker BJ, Brewer D, Spurgeon SE. American Journal of Hematology.  2017 Jan. PMID: 27761930 
  • BRAF V600E is also seen in unclassifiable splenic B-cell lymphoma/leukemia, a potential mimic of hairy cell leukemia.Raess PW, Mintzer D, Husson M, Nakashima MO, Morrissette JJ, Daber R, Bagg A. Blood. 2013 Oct 24. PMID: 24159168